Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

A study identifies promising compounds targeting PI3Kα for the treatment of triple-negative breast cancer, offering new ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

ETX-636 has a differentiated preclinical profile and the potential to deliver clinical benefit to patients with tumors harboring all forms of mutant PI3Kα. The ETX-636 preclinical data is being ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...

Scorpion's lead drug asset, a mutant-selective PI3Kα inhibitor known as STX-478, is currently in Phase 1/2 testing for the treatment of breast cancer and other solid tumors. Under the deal ...

“I am excited to join Totus Medicines and leverage my expertise in the biotech sector to support the advancement of our pipeline, which addresses critical unmet medical needs across multiple ...

“We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...